RachelPrestiMD
Infectious Disease • Saint Louis, MOHIV/AIDS Medicine
Assistant Professor, Internal Medicine, Washington University School of Medicine
Dr. Presti is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
620 S Taylor Ave
# Dv
Saint Louis, MO 63110Phone+1 314-362-9098Fax+1 314-362-9851
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Infectious Disease, 2003 - 2006- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2001 - 2003
- Washington University in St. Louis School of MedicineClass of 2001
Certifications & Licensure
MO State Medical License 2006 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant Start of enrollment: 2018 Mar 19
Publications & Presentations
PubMed
- Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection.Myra Happe, Rebecca M Lynch, Carl J Fichtenbaum, Sonya L Heath, Susan L Koletar
JCI Insight. 2025-02-24 - 1 citationsNeutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.Youyi Fong, Lauren Dang, Bo Zhang, Jonathan Fintzi, Shiyu Chen
Clinical Infectious Diseases. 2025-02-05 - Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.Bo Zhang, Youyi Fong, Lauren Dang, Jonathan Fintzi, Shiyu Chen
Nature Communications. 2025-01-17
Press Mentions
$12 Million Grant Aimed at Probing How Vaccines Induce Lasting ImmunitySeptember 26th, 2024- $6.2 Million to Help Develop Gene Therapy for HIVApril 18th, 2024
- FDA Advisers Consider Changing COVID Vaccine to Target Latest Omicron StrainJune 16th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
